Moderna stock is already trading up 58% this year. Could this finally be the start of a sustained bull run for the pharmaceutical stock? This is particularly significant since patients with this disease are typically at high risk of disease recurrence, a problem Moderna's intismeran autogene could help address. These successes were fairly modest compared to what we could see with intismeran autogene. Within the next three years, Moderna's lineup of approved products could look different, with intismeran autogene, and, potentially, others.